Clinical-stage oncology company Onward Therapeutics Inc announced on Tuesday that it has closed its Series B financing of NTD900m (approximately USD28m).
The round was raised in two closings, the second of which took place in October 2026. It is the company's first capital increase in Taiwan since it completed its share exchange and moved its global headquarters from Switzerland to Taiwan in October 2025. Before the share exchange, the company had raised a total of CHF75.5m (approximately USD90m) in its previous rounds. Proceeds from the Series B will fund the company's clinical programmes, the manufacturing of clinical supplies, and early-stage R&D.
Existing individual and institutional shareholders, including CDIB Capital Healthcare Ventures and Hong Kong Chlitina International, continued to support the company in this round. New institutional investors include Beiley Biofund, Everbright Biofund, Test Rite International Co Ltd, Grand Fortune Venture Capital, Hercules Bioventure Partners, MitoBitTech Venture, and Top Taiwan Venture Capital. A number of individual investors also joined the round.
Onward Therapeutics' portfolio includes two clinical-stage programmes (an innovative bispecific antibody and an allogeneic cell therapy) and two early-stage drug discovery programmes.
Onward Therapeutics has signed a listing advisory agreement with a securities firm and begun preparing to register on the Taipei Exchange's Emerging Stock Board by the end of 2027. In addition, the company says that it plans to expand its team and start clinical trials in Taiwan, further strengthening its local R&D presence.
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London